OPK
Opko Health, Inc. Health Care Pharmaceutical Preparations Russell 3000
$1.66Close
$1.3BMarket cap
$1.10 – $1.7352-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 86 · stronger than 86% of stocks over 12 months
- Near its high 4% below its 52-week high
- Volume drying up last 10 days 28% under the 50-day average
- Accumulation up-day volume 1.8× down-day volume over 50 sessions
Cautions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
up 1.8%
price change
1mo
up 3.1%
price change
12-month return
up 14%
market up 11% ·
its own up 5%
F-score
4 / 9
Weak
Altman Z
-0.09
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.0×
price / book
Earnings yield
down 12.4%
EBIT / enterprise value
Cheaper than
35%
of the market · expensive
Revenue growth
down 15%
year on year
EPS growth
—
latest quarter
Sales growth
up 4%
latest quarter · +21 pts
ROE
down 17140%
return on equity
Free cash margin
down 31%
-$190.8M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- issued more shares
- assets working less efficiently
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
Repair signals
- Long-term debt down 25% ($0.0B → $0.0B)
- Gross margin 30.6% → 33.9%
Trade setup
ATR%
4.8%
$0.08 a day · 2×ATR $1.50
RS
86 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
1.82
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 12.6% over the year, from 701m to 790m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 14.9% over the year, from $713.1M to $606.9M.
Last reported
Jul 27, 2026
Last shock
Jul 29, 2026-17% in one session2.3× volumeon results+21% since
Financials
- Gross 34%
- Net -37187%
- Free cash -31%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.8B | $1.0B | $863.5M | $713.1M | $606.9M |
| Gross margin | — | — | 29% | 37% | 31% | 34% |
| Operating income | $57.7M | $18.8M | -$226.3M | -$157.0M | -$152.1M | -$117.4M |
| Net income | $30.6M | -$30.1B | -$328.4B | -$188.9B | -$53.2B | -$225.7B |
| Net margin | 2% | -1698% | -32703% | -21872% | -7463% | -37187% |
| Earnings per share | $0.05 | -$46.51 | -$456.71 | -$251.23 | -$76.69 | -$300.45 |
| Free cash flow | $5.8M | $6.2M | -$119.8M | -$44.5M | -$208.5M | -$190.8M |
| Free cash margin | 0% | 0% | -12% | -5% | -29% | -31% |
| Cash | $72.2M | $134.7M | $153.2M | $95.9M | $426.6M | $364.4M |
| Long-term debt | $3.8M | $205.3M | $9.3M | $7.7M | $3.0M | $2.3M |
| Shareholders' equity | $1.7B | $1.7B | $1.6B | $1.4B | $1.4B | $1.3B |
| Shares outstanding | 670.59m | 690.08m | 781.31m | 781.94m | 701.35m | 789.92m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 27, 2026 | Quarterly ↗ | Jun 30, 2026 | 27d |
| Apr 28, 2026 | Quarterly ↗ | Mar 31, 2026 | 28d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Oct 29, 2025 | Quarterly ↗ | Sep 30, 2025 | 29d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 1, 2024 | Annual ↗ | Dec 31, 2023 | 61d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 15, 2026 | Material agreement ↗ |
| Oct 2, 2026 | Other events ↗ |
| Aug 14, 2026 | Material agreement · New obligation ↗ |
| Jul 27, 2026 | Results ↗ |
| Jun 18, 2026 | Shareholder vote ↗ |
| Apr 28, 2026 | Results ↗ |
| Mar 19, 2026 | Director or officer change ↗ |
| Feb 26, 2026 | Results ↗ |
| Oct 29, 2025 | Results ↗ |
| Sep 15, 2025 | Regulation FD · Other events ↗ |
| Jul 31, 2025 | Results ↗ |
| May 29, 2025 | Director or officer change ↗ |